May 05, 2020
Journal of Neuroinflammation Article Shows ZyVersa's Inflammasome Inhibitor, IC 100, Improves Functional Outcomes in an Animal Model of Multiple Sclerosis
Jan 30, 2020
ZyVersa Therapeutics Featured in Business Worldwide Magazine's Winter Edition as One of the 20 Most Innovative Companies to Watch
Jan 27, 2020
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
Jan 20, 2020
ZyVersa Therapeutics Releases Video Demonstrating How Inflammasomes Stimulate and Perpetuate Inflammation, and How a Novel Inflammasome Inhibitor, IC 100, Has Potential to Control Chronic Damaging Inflammation Associated with Inflammatory Diseases
Nov 20, 2019
New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer's Disease
Oct 28, 2019
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the Inaugural Inflammasome Therapeutics Summit on October 30th, 2019
Sep 25, 2019
Interview with ZyVersa Therapeutics' CEO, Stephen C. Glover, Published in CEOCFO Magazine
Sep 19, 2019
ZyVersa Therapeutics Unveils a White Paper Fostering Education About Inflammasomes and Their Potential as a Promising Therapeutic and Diagnostic Target for Inflammatory Diseases
Sep 12, 2019
ZyVersa Therapeutics' Perspectives on Inflammasomes Reported in BIOCENTURY Innovations Article
Sep 05, 2019
ZyVersa Therapeutics Advances Development of Lead Inflammasome Inhibitor Candidate, IC 100
May 21, 2019
Experts on the Forefront of Inflammasome Research Will Serve on ZyVersa Therapeutics' Inaugural Immunology Scientific Advisory Board
Apr 22, 2019
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor
Apr 01, 2019
Novartis to Acquire IFM Tre to Develop First-In-Class NLRP3 Antagonist Portfolio Targeting Innate Immune System
Mar 28, 2019
IFM Therapeutics Announces Dosing of First Subjects in Phase 1 Healthy Volunteer Study of Lead NLRP3 Antagonist, IFM-2427
Dec 18, 2018
IFM Therapeutics Announces Newly Discovered Mechanism of Inflammatory Processes in the Body
Jul 30, 2018
IFM Therapeutics Announces New Publication in Nature Reviews Drug Discovery Examining NLRP3 as a Target in Serious Inflammatory and Immune-Mediated Diseases
Jul 19, 2018
IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases
Jan 11, 2018
Western Diet Causes Long-Term Impact on Body's Immune System Even After Dietary Changes
Dec 20, 2017
New Research Demonstrates Direct Link between Inflammasome Activation and Amyloid-b Pathology in Alzheimer's Disease
Dec 20, 2017
IFM Therapeutics LLC Appoints Dr. Michael Heneka to Clinical Advisory Board